DE102005057408A1 - Sulfamoylsulfonat-Prodrugs - Google Patents

Sulfamoylsulfonat-Prodrugs Download PDF

Info

Publication number: DE102005057408A1
Authority: DE; Germany
Prior art keywords: sulfamoylphenylsulfonate; quinine; prodrugs; sulfamoylsulfonate; drug
Prior art date: 2005-11-30
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Ceased

Application number

DE102005057408A

Other languages

German (de)

English (en)

Inventor

Ralf Wyrwa

Reinhard Nubbemeyer

Ursula Ganzer

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Bayer Pharma AG

Original Assignee

Bayer Schering Pharma AG

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-11-30

Filing date

2005-11-30

Publication date

2007-05-31

2005-11-30 Application filed by Bayer Schering Pharma AG filed Critical Bayer Schering Pharma AG

2005-11-30 Priority to DE102005057408A priority Critical patent/DE102005057408A1/de

2006-11-27 Priority to KR1020087015775A priority patent/KR20080072956A/ko

2006-11-27 Priority to CA002632272A priority patent/CA2632272A1/fr

2006-11-27 Priority to AU2006319380A priority patent/AU2006319380A1/en

2006-11-27 Priority to EA200801306A priority patent/EA200801306A1/xx

2006-11-27 Priority to CNA2006800449086A priority patent/CN101316858A/zh

2006-11-27 Priority to EP06829354A priority patent/EP1957513A2/fr

2006-11-27 Priority to PCT/EP2006/011726 priority patent/WO2007062874A2/fr

2006-11-27 Priority to JP2008542678A priority patent/JP2009517424A/ja

2006-11-27 Priority to BRPI0619253-0A priority patent/BRPI0619253A2/pt

2006-11-29 Priority to US11/605,473 priority patent/US20070135375A1/en

2007-05-31 Publication of DE102005057408A1 publication Critical patent/DE102005057408A1/de

2008-05-20 Priority to IL191570A priority patent/IL191570A0/en

2008-05-21 Priority to CR10003A priority patent/CR10003A/es

2008-05-30 Priority to EC2008008489A priority patent/ECSP088489A/es

2008-06-27 Priority to NO20082915A priority patent/NO20082915L/no

2008-06-27 Priority to ZA200805659A priority patent/ZA200805659B/xx

Status Ceased legal-status Critical Current

Links

239000000651 prodrug Substances 0.000 title claims abstract description 24
229940002612 prodrug Drugs 0.000 title claims abstract description 24
UYSRSLSTXYYNEW-UHFFFAOYSA-N NS(=O)(=O)S(O)(=O)=O Chemical compound NS(=O)(=O)S(O)(=O)=O UYSRSLSTXYYNEW-UHFFFAOYSA-N 0.000 title claims abstract description 16
210000003743 erythrocyte Anatomy 0.000 title claims description 10
201000010099 disease Diseases 0.000 title claims description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 5
230000035558 fertility Effects 0.000 title claims description 4
238000002657 hormone replacement therapy Methods 0.000 title claims description 3
229940088597 hormone Drugs 0.000 title 1
239000005556 hormone Substances 0.000 title 1
244000045947 parasite Species 0.000 title 1
239000003814 drug Substances 0.000 claims abstract description 31
229940079593 drug Drugs 0.000 claims abstract description 24
BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims abstract description 23
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 8
125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 7
125000000732 arylene group Chemical group 0.000 claims abstract description 5
239000013543 active substance Substances 0.000 claims abstract description 4
230000000694 effects Effects 0.000 claims abstract description 4
238000004519 manufacturing process Methods 0.000 claims abstract 8
-1 estrogens Chemical class 0.000 claims description 33
150000001875 compounds Chemical class 0.000 claims description 32
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 18
LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 claims description 11
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 10
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 9
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims description 8
LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 claims description 7
238000011321 prophylaxis Methods 0.000 claims description 7
238000011282 treatment Methods 0.000 claims description 7
KMPWYEUPVWOPIM-UHFFFAOYSA-N cinchonidine Natural products C1=CC=C2C(C(C3N4CCC(C(C4)C=C)C3)O)=CC=NC2=C1 KMPWYEUPVWOPIM-UHFFFAOYSA-N 0.000 claims description 6
HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 claims description 6
229960002555 zidovudine Drugs 0.000 claims description 6
YSGQGNQWBLYHPE-CFUSNLFHSA-N (7r,8r,9s,10r,13s,14s,17s)-17-hydroxy-7,13-dimethyl-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-one Chemical compound C1C[C@]2(C)[C@@H](O)CC[C@H]2[C@@H]2[C@H](C)CC3=CC(=O)CC[C@@H]3[C@H]21 YSGQGNQWBLYHPE-CFUSNLFHSA-N 0.000 claims description 5
235000001258 Cinchona calisaya Nutrition 0.000 claims description 5
229910021529 ammonia Inorganic materials 0.000 claims description 5
239000003430 antimalarial agent Substances 0.000 claims description 5
238000000034 method Methods 0.000 claims description 5
239000002777 nucleoside Substances 0.000 claims description 5
239000000583 progesterone congener Substances 0.000 claims description 5
229960000948 quinine Drugs 0.000 claims description 5
150000003431 steroids Chemical class 0.000 claims description 5
235000000346 sugar Nutrition 0.000 claims description 5
WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 claims description 4
XEEQGYMUWCZPDN-DOMZBBRYSA-N (-)-(11S,2'R)-erythro-mefloquine Chemical compound C([C@@H]1[C@@H](O)C=2C3=CC=CC(=C3N=C(C=2)C(F)(F)F)C(F)(F)F)CCCN1 XEEQGYMUWCZPDN-DOMZBBRYSA-N 0.000 claims description 4
NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 claims description 4
ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims description 4
239000003098 androgen Substances 0.000 claims description 4
229960003473 androstanolone Drugs 0.000 claims description 4
229940033495 antimalarials Drugs 0.000 claims description 4
238000003776 cleavage reaction Methods 0.000 claims description 4
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 4
AZFLJNIPTRTECV-FUMNGEBKSA-N dienogest Chemical compound C1CC(=O)C=C2CC[C@@H]([C@H]3[C@@](C)([C@](CC3)(O)CC#N)CC3)C3=C21 AZFLJNIPTRTECV-FUMNGEBKSA-N 0.000 claims description 4
229960003309 dienogest Drugs 0.000 claims description 4
239000000262 estrogen Substances 0.000 claims description 4
229940011871 estrogen Drugs 0.000 claims description 4
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims description 4
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 4
XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 claims description 4
229960004171 hydroxychloroquine Drugs 0.000 claims description 4
229930013032 isoflavonoid Natural products 0.000 claims description 4
235000012891 isoflavonoids Nutrition 0.000 claims description 4
229960004400 levonorgestrel Drugs 0.000 claims description 4
229960001962 mefloquine Drugs 0.000 claims description 4
229940053934 norethindrone Drugs 0.000 claims description 4
VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 claims description 4
125000003835 nucleoside group Chemical group 0.000 claims description 4
230000007017 scission Effects 0.000 claims description 4
229960003604 testosterone Drugs 0.000 claims description 4
RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims description 4
QAGYKUNXZHXKMR-UHFFFAOYSA-N CPD000469186 Natural products CC1=C(O)C=CC=C1C(=O)NC(C(O)CN1C(CC2CCCCC2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-UHFFFAOYSA-N 0.000 claims description 3
239000003418 antiprogestin Substances 0.000 claims description 3
229960001169 brivudine Drugs 0.000 claims description 3
ODZBBRURCPAEIQ-PIXDULNESA-N helpin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(\C=C\Br)=C1 ODZBBRURCPAEIQ-PIXDULNESA-N 0.000 claims description 3
CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 claims description 3
229960001936 indinavir Drugs 0.000 claims description 3
150000003817 isoflavonoid derivatives Chemical class 0.000 claims description 3
229960000884 nelfinavir Drugs 0.000 claims description 3
229960005179 primaquine Drugs 0.000 claims description 3
INDBQLZJXZLFIT-UHFFFAOYSA-N primaquine Chemical compound N1=CC=CC2=CC(OC)=CC(NC(C)CCCN)=C21 INDBQLZJXZLFIT-UHFFFAOYSA-N 0.000 claims description 3
239000002379 progesterone receptor modulator Substances 0.000 claims description 3
230000003637 steroidlike Effects 0.000 claims description 3
PROQIPRRNZUXQM-UHFFFAOYSA-N (16alpha,17betaOH)-Estra-1,3,5(10)-triene-3,16,17-triol Natural products OC1=CC=C2C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 PROQIPRRNZUXQM-UHFFFAOYSA-N 0.000 claims description 2
IEXUMDBQLIVNHZ-YOUGDJEHSA-N (8s,11r,13r,14s,17s)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(3-hydroxypropyl)-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(O)CCCO)[C@@]2(C)C1 IEXUMDBQLIVNHZ-YOUGDJEHSA-N 0.000 claims description 2
125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 2
125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 2
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims description 2
NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 claims description 2
ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 claims description 2
229930024421 Adenine Natural products 0.000 claims description 2
GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims description 2
206010006187 Breast cancer Diseases 0.000 claims description 2
208000026310 Breast neoplasm Diseases 0.000 claims description 2
HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 claims description 2
201000009273 Endometriosis Diseases 0.000 claims description 2
206010058359 Hypogonadism Diseases 0.000 claims description 2
PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims description 2
229960000643 adenine Drugs 0.000 claims description 2
208000026935 allergic disease Diseases 0.000 claims description 2
HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 claims description 2
229940030486 androgens Drugs 0.000 claims description 2
GJMNAFGEUJBOCE-MEQIQULJSA-N asoprisnil Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@]([C@]3(C2)C)(COC)OC)=CC=C(\C=N\O)C=C1 GJMNAFGEUJBOCE-MEQIQULJSA-N 0.000 claims description 2
229950003620 asoprisnil Drugs 0.000 claims description 2
239000000969 carrier Substances 0.000 claims description 2
229940104302 cytosine Drugs 0.000 claims description 2
METQSPRSQINEEU-UHFFFAOYSA-N dihydrospirorenone Natural products CC12CCC(C3(CCC(=O)C=C3C3CC33)C)C3C1C1CC1C21CCC(=O)O1 METQSPRSQINEEU-UHFFFAOYSA-N 0.000 claims description 2
229960004845 drospirenone Drugs 0.000 claims description 2
METQSPRSQINEEU-HXCATZOESA-N drospirenone Chemical compound C([C@]12[C@H]3C[C@H]3[C@H]3[C@H]4[C@@H]([C@]5(CCC(=O)C=C5[C@@H]5C[C@@H]54)C)CC[C@@]31C)CC(=O)O2 METQSPRSQINEEU-HXCATZOESA-N 0.000 claims description 2
229960005309 estradiol Drugs 0.000 claims description 2
229930182833 estradiol Natural products 0.000 claims description 2
229960001348 estriol Drugs 0.000 claims description 2
PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 claims description 2
229940045109 genistein Drugs 0.000 claims description 2
TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 claims description 2
235000006539 genistein Nutrition 0.000 claims description 2
ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 claims description 2
229960000890 hydrocortisone Drugs 0.000 claims description 2
230000003301 hydrolyzing effect Effects 0.000 claims description 2
208000027866 inflammatory disease Diseases 0.000 claims description 2
230000002757 inflammatory effect Effects 0.000 claims description 2
230000002401 inhibitory effect Effects 0.000 claims description 2
229960003248 mifepristone Drugs 0.000 claims description 2
VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 claims description 2
229960004719 nandrolone Drugs 0.000 claims description 2
229950011093 onapristone Drugs 0.000 claims description 2
229940095745 sex hormone and modulator of the genital system progesterone receptor modulator Drugs 0.000 claims description 2
229940113082 thymine Drugs 0.000 claims description 2
229940035893 uracil Drugs 0.000 claims description 2
238000002560 therapeutic procedure Methods 0.000 claims 4
239000004480 active ingredient Substances 0.000 claims 3
QTQWMSOQOSJFBV-UHFFFAOYSA-N pamaquine Chemical compound C1=CN=C2C(NC(C)CCCN(CC)CC)=CC(OC)=CC2=C1 QTQWMSOQOSJFBV-UHFFFAOYSA-N 0.000 claims 3
229950000466 pamaquine Drugs 0.000 claims 3
NNKXWRRDHYTHFP-HZQSTTLBSA-N (r)-[(2s,4s,5r)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol;hydron;dichloride Chemical compound Cl.Cl.C([C@H]([C@H](C1)C=C)C2)CN1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 NNKXWRRDHYTHFP-HZQSTTLBSA-N 0.000 claims 2
239000001096 (4-ethenyl-1-azabicyclo[2.2.2]octan-7-yl)-(6-methoxyquinolin-4-yl)methanol hydrochloride Substances 0.000 claims 1
AKYHKWQPZHDOBW-UHFFFAOYSA-N (5-ethenyl-1-azabicyclo[2.2.2]octan-7-yl)-(6-methoxyquinolin-4-yl)methanol Chemical compound OS(O)(=O)=O.C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 AKYHKWQPZHDOBW-UHFFFAOYSA-N 0.000 claims 1
WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 claims 1
XHKUDCCTVQUHJQ-BILMMMPYSA-N (r)-[(2s,4s,5r)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C([C@H]([C@H](C1)C=C)C2)CN1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 XHKUDCCTVQUHJQ-BILMMMPYSA-N 0.000 claims 1
MAYUSTFJKJSJNC-DSXUQNDKSA-N (r)-[(2s,4s,5r)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol;2-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=CC=C1O.C([C@H]([C@H](C1)C=C)C2)CN1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 MAYUSTFJKJSJNC-DSXUQNDKSA-N 0.000 claims 1
GKRXTXTYZVRRAI-HZQSTTLBSA-N (r)-[(2s,4s,5r)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol;dihydrobromide Chemical compound Br.Br.C([C@H]([C@H](C1)C=C)C2)CN1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 GKRXTXTYZVRRAI-HZQSTTLBSA-N 0.000 claims 1
LKUVXQMSYPYURB-DSXUQNDKSA-N (r)-[(2s,4s,5r)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol;formic acid Chemical compound OC=O.C([C@H]([C@H](C1)C=C)C2)CN1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LKUVXQMSYPYURB-DSXUQNDKSA-N 0.000 claims 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims 1
239000001576 FEMA 2977 Substances 0.000 claims 1
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims 1
206010060862 Prostate cancer Diseases 0.000 claims 1
208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
NSBRKSWSLRQPJW-WWLNLUSPSA-N [(r)-[(2s,4s,5r)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methyl] ethyl carbonate Chemical compound C1=C(OC)C=C2C([C@H]([C@H]3N4CC[C@H]([C@H](C4)C=C)C3)OC(=O)OCC)=CC=NC2=C1 NSBRKSWSLRQPJW-WWLNLUSPSA-N 0.000 claims 1
229960000981 artemether Drugs 0.000 claims 1
229960002970 artemotil Drugs 0.000 claims 1
NLYNIRQVMRLPIQ-XQLAAWPRSA-N artemotil Chemical compound C1C[C@H]2[C@H](C)CC[C@H]3[C@@H](C)[C@@H](OCC)O[C@H]4[C@]32OO[C@@]1(C)O4 NLYNIRQVMRLPIQ-XQLAAWPRSA-N 0.000 claims 1
FIHJKUPKCHIPAT-AHIGJZGOSA-N artesunate Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@@H](OC(=O)CCC(O)=O)[C@@H]4C FIHJKUPKCHIPAT-AHIGJZGOSA-N 0.000 claims 1
229960004991 artesunate Drugs 0.000 claims 1
150000001720 carbohydrates Chemical class 0.000 claims 1
229960003677 chloroquine Drugs 0.000 claims 1
WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 claims 1
KMPWYEUPVWOPIM-LSOMNZGLSA-N cinchonine Chemical compound C1=CC=C2C([C@@H]([C@H]3N4CC[C@H]([C@H](C4)C=C)C3)O)=CC=NC2=C1 KMPWYEUPVWOPIM-LSOMNZGLSA-N 0.000 claims 1
SXYIRMFQILZOAM-HVNFFKDJSA-N dihydroartemisinin methyl ether Chemical compound C1C[C@H]2[C@H](C)CC[C@H]3[C@@H](C)[C@@H](OC)O[C@H]4[C@]32OO[C@@]1(C)O4 SXYIRMFQILZOAM-HVNFFKDJSA-N 0.000 claims 1
230000003054 hormonal effect Effects 0.000 claims 1
239000002207 metabolite Substances 0.000 claims 1
NPAGDVCDWIYMMC-IZPLOLCNSA-N nandrolone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 NPAGDVCDWIYMMC-IZPLOLCNSA-N 0.000 claims 1
230000003071 parasitic effect Effects 0.000 claims 1
125000000843 phenylene group Chemical class C1(=C(C=CC=C1)*)* 0.000 claims 1
230000002265 prevention Effects 0.000 claims 1
229960005385 proguanil Drugs 0.000 claims 1
SSOLNOMRVKKSON-UHFFFAOYSA-N proguanil Chemical compound CC(C)\N=C(/N)N=C(N)NC1=CC=C(Cl)C=C1 SSOLNOMRVKKSON-UHFFFAOYSA-N 0.000 claims 1
125000005551 pyridylene group Chemical class 0.000 claims 1
229960000611 pyrimethamine Drugs 0.000 claims 1
WKSAUQYGYAYLPV-UHFFFAOYSA-N pyrimethamine Chemical compound CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1 WKSAUQYGYAYLPV-UHFFFAOYSA-N 0.000 claims 1
229960001463 quinine bisulfate Drugs 0.000 claims 1
229960002522 quinine dihydrochloride Drugs 0.000 claims 1
229960001811 quinine hydrochloride Drugs 0.000 claims 1
229960002991 quinine salicylate Drugs 0.000 claims 1
229960003110 quinine sulfate Drugs 0.000 claims 1
RONWGALEIBILOG-VMJVVOMYSA-N quinine sulfate Chemical compound [H+].[H+].[O-]S([O-])(=O)=O.C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21.C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 RONWGALEIBILOG-VMJVVOMYSA-N 0.000 claims 1
230000001225 therapeutic effect Effects 0.000 claims 1
125000000753 cycloalkyl group Chemical group 0.000 abstract description 3
125000000217 alkyl group Chemical group 0.000 abstract description 2
239000008177 pharmaceutical agent Substances 0.000 abstract description 2
230000003266 anti-allergic effect Effects 0.000 abstract 1
230000003110 anti-inflammatory effect Effects 0.000 abstract 1
230000002141 anti-parasite Effects 0.000 abstract 1
239000003096 antiparasitic agent Substances 0.000 abstract 1
239000000824 cytostatic agent Substances 0.000 abstract 1
230000001085 cytostatic effect Effects 0.000 abstract 1
230000010534 mechanism of action Effects 0.000 abstract 1
239000002423 protozoacide Substances 0.000 abstract 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 12
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 12
239000000243 solution Substances 0.000 description 12
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
239000011541 reaction mixture Substances 0.000 description 9
239000000741 silica gel Substances 0.000 description 9
229910002027 silica gel Inorganic materials 0.000 description 9
238000004128 high performance liquid chromatography Methods 0.000 description 7
238000005160 1H NMR spectroscopy Methods 0.000 description 6
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
229910052786 argon Inorganic materials 0.000 description 6
125000004432 carbon atom Chemical group C* 0.000 description 6
238000004587 chromatography analysis Methods 0.000 description 6
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 5
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 5
235000011114 ammonium hydroxide Nutrition 0.000 description 5
ALIQZUMMPOYCIS-UHFFFAOYSA-N benzene-1,3-disulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC(S(Cl)(=O)=O)=C1 ALIQZUMMPOYCIS-UHFFFAOYSA-N 0.000 description 5
210000004051 gastric juice Anatomy 0.000 description 5
230000007062 hydrolysis Effects 0.000 description 5
238000006460 hydrolysis reaction Methods 0.000 description 5
239000012074 organic phase Substances 0.000 description 5
239000003826 tablet Substances 0.000 description 5
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
239000008298 dragée Substances 0.000 description 4
125000005843 halogen group Chemical group 0.000 description 4
238000011002 quantification Methods 0.000 description 4
108090000790 Enzymes Proteins 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
108090000371 Esterases Proteins 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
239000008186 active pharmaceutical agent Substances 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
239000002775 capsule Substances 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
239000000460 chlorine Substances 0.000 description 3
229940088679 drug related substance Drugs 0.000 description 3
229940088598 enzyme Drugs 0.000 description 3
230000000968 intestinal effect Effects 0.000 description 3
210000000936 intestine Anatomy 0.000 description 3
210000004185 liver Anatomy 0.000 description 3
125000002560 nitrile group Chemical group 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
239000002244 precipitate Substances 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
238000003756 stirring Methods 0.000 description 3
150000003871 sulfonates Chemical class 0.000 description 3
239000000725 suspension Substances 0.000 description 3
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
101000984236 Homo sapiens Carbonic anhydrase 1 Proteins 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
239000002253 acid Substances 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
125000003118 aryl group Chemical group 0.000 description 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
125000002837 carbocyclic group Chemical group 0.000 description 2
150000001733 carboxylic acid esters Chemical class 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
229910052801 chlorine Inorganic materials 0.000 description 2
150000001805 chlorine compounds Chemical class 0.000 description 2
238000000576 coating method Methods 0.000 description 2
239000002274 desiccant Substances 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
238000001914 filtration Methods 0.000 description 2
239000011737 fluorine Substances 0.000 description 2
229910052731 fluorine Inorganic materials 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
125000005842 heteroatom Chemical group 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
238000005259 measurement Methods 0.000 description 2
QAGYKUNXZHXKMR-HKWSIXNMSA-N nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 description 2
238000004848 nephelometry Methods 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
239000001301 oxygen Substances 0.000 description 2
229910052760 oxygen Inorganic materials 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
239000008055 phosphate buffer solution Substances 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
235000010356 sorbitol Nutrition 0.000 description 2
210000002784 stomach Anatomy 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000011593 sulfur Substances 0.000 description 2
229910052717 sulfur Inorganic materials 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
238000012360 testing method Methods 0.000 description 2
FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
230000002110 toxicologic effect Effects 0.000 description 2
231100000027 toxicology Toxicity 0.000 description 2
MRCKRGSNLOHYRA-UHFFFAOYSA-N (2-nitrophenyl) acetate Chemical compound CC(=O)OC1=CC=CC=C1[N+]([O-])=O MRCKRGSNLOHYRA-UHFFFAOYSA-N 0.000 description 1
QPOSLUJQXMVNGD-NTYLBUJVSA-N (8r,9s,13s,14s,17s)-3-[tert-butyl(dimethyl)silyl]oxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-ol Chemical compound C1C[C@]2(C)[C@@H](O)CC[C@H]2[C@@H]2CCC3=CC(O[Si](C)(C)C(C)(C)C)=CC=C3[C@H]21 QPOSLUJQXMVNGD-NTYLBUJVSA-N 0.000 description 1
ASLVVDVJYDCLPC-UHFFFAOYSA-N 2-sulfamoylbenzenesulfonic acid Chemical compound NS(=O)(=O)C1=CC=CC=C1S(O)(=O)=O ASLVVDVJYDCLPC-UHFFFAOYSA-N 0.000 description 1
PWSQDFHPBVRXTQ-UHFFFAOYSA-N 3-sulfamoylbenzenesulfonyl chloride Chemical compound NS(=O)(=O)C1=CC=CC(S(Cl)(=O)=O)=C1 PWSQDFHPBVRXTQ-UHFFFAOYSA-N 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical class OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
102100024633 Carbonic anhydrase 2 Human genes 0.000 description 1
101710167917 Carbonic anhydrase 2 Proteins 0.000 description 1
108090000209 Carbonic anhydrases Proteins 0.000 description 1
102000003846 Carbonic anhydrases Human genes 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
239000004129 EU approved improving agent Substances 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
239000001828 Gelatine Substances 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
101000760643 Homo sapiens Carbonic anhydrase 2 Proteins 0.000 description 1
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
238000012404 In vitro experiment Methods 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
102000057297 Pepsin A Human genes 0.000 description 1
108090000284 Pepsin A Proteins 0.000 description 1
229920001800 Shellac Polymers 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical group C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 1
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 1
239000012062 aqueous buffer Substances 0.000 description 1
125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
125000002619 bicyclic group Chemical group 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
229940081734 cellulose acetate phthalate Drugs 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
239000012050 conventional carrier Substances 0.000 description 1
238000001816 cooling Methods 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
239000003246 corticosteroid Substances 0.000 description 1
229960001334 corticosteroids Drugs 0.000 description 1
150000001885 cortisol derivatives Chemical class 0.000 description 1
229940109275 cyclamate Drugs 0.000 description 1
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
239000007941 film coated tablet Substances 0.000 description 1
238000010579 first pass effect Methods 0.000 description 1
125000002541 furyl group Chemical group 0.000 description 1
239000007789 gas Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
125000001072 heteroaryl group Chemical group 0.000 description 1
125000005549 heteroarylene group Chemical group 0.000 description 1
125000002883 imidazolyl group Chemical group 0.000 description 1
229960003444 immunosuppressant agent Drugs 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
125000001041 indolyl group Chemical group 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
239000011261 inert gas Substances 0.000 description 1
239000012442 inert solvent Substances 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
125000005956 isoquinolyl group Chemical group 0.000 description 1
125000001786 isothiazolyl group Chemical group 0.000 description 1
125000000842 isoxazolyl group Chemical group 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
201000004792 malaria Diseases 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
238000002156 mixing Methods 0.000 description 1
125000002950 monocyclic group Chemical group 0.000 description 1
REACBNMPQDINOF-YBBIQVIJSA-N nandrolone cyclotate Chemical compound C1CC(C)(C=C2)CCC12C(=O)O[C@H]1CC[C@H]2[C@H](CCC=3[C@@H]4CCC(=O)C=3)[C@@H]4CC[C@@]21C REACBNMPQDINOF-YBBIQVIJSA-N 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
150000003833 nucleoside derivatives Chemical class 0.000 description 1
125000001715 oxadiazolyl group Chemical group 0.000 description 1
125000002971 oxazolyl group Chemical group 0.000 description 1
229940111202 pepsin Drugs 0.000 description 1
125000005562 phenanthrylene group Chemical group 0.000 description 1
239000006187 pill Substances 0.000 description 1
229920002689 polyvinyl acetate Polymers 0.000 description 1
239000011118 polyvinyl acetate Substances 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
210000002307 prostate Anatomy 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
125000003373 pyrazinyl group Chemical group 0.000 description 1
125000003226 pyrazolyl group Chemical group 0.000 description 1
125000002098 pyridazinyl group Chemical group 0.000 description 1
125000004076 pyridyl group Chemical group 0.000 description 1
125000000714 pyrimidinyl group Chemical group 0.000 description 1
125000000168 pyrrolyl group Chemical group 0.000 description 1
125000005493 quinolyl group Chemical group 0.000 description 1
125000006413 ring segment Chemical group 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
229940081974 saccharin Drugs 0.000 description 1
235000019204 saccharin Nutrition 0.000 description 1
239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
239000004208 shellac Substances 0.000 description 1
235000013874 shellac Nutrition 0.000 description 1
229940113147 shellac Drugs 0.000 description 1
ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
125000006850 spacer group Chemical group 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
IIACRCGMVDHOTQ-UHFFFAOYSA-M sulfamate Chemical compound NS([O-])(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-M 0.000 description 1
IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid Chemical class NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 1
AMEGLNRBNAQVQM-UHFFFAOYSA-N sulfamoyl benzenesulfonate Chemical compound S(N)(=O)(=O)OS(=O)(=O)C1=CC=CC=C1 AMEGLNRBNAQVQM-UHFFFAOYSA-N 0.000 description 1
229940124530 sulfonamide Drugs 0.000 description 1
125000000565 sulfonamide group Chemical group 0.000 description 1
150000003456 sulfonamides Chemical class 0.000 description 1
150000003459 sulfonic acid esters Chemical class 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
125000001113 thiadiazolyl group Chemical group 0.000 description 1
125000000335 thiazolyl group Chemical group 0.000 description 1
125000001544 thienyl group Chemical group 0.000 description 1
OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
125000004306 triazinyl group Chemical group 0.000 description 1
125000001425 triazolyl group Chemical group 0.000 description 1
125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 description 1
MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical group COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
235000012141 vanillin Nutrition 0.000 description 1
230000003612 virological effect Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0072—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the A ring of the steroid being aromatic
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0038—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 with an androstane skeleton, including 18- or 19-substituted derivatives, 18-nor derivatives and also derivatives where position 17-beta is substituted by a carbon atom not directly bonded to a further carbon atom and not being part of an amide group

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Immunology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)

DE102005057408A 2005-11-30 2005-11-30 Sulfamoylsulfonat-Prodrugs Ceased DE102005057408A1 (de)

Priority Applications (16)

Application Number	Priority Date	Filing Date	Title
DE102005057408A DE102005057408A1 (de)	2005-11-30	2005-11-30	Sulfamoylsulfonat-Prodrugs
PCT/EP2006/011726 WO2007062874A2 (fr)	2005-11-30	2006-11-27	Promedicaments de sulfonate de sulfamoyle
CA002632272A CA2632272A1 (fr)	2005-11-30	2006-11-27	Promedicaments de sulfonate de sulfamoyle
AU2006319380A AU2006319380A1 (en)	2005-11-30	2006-11-27	Sulfamoyl sulfonate prodrugs
EA200801306A EA200801306A1 (ru)	2005-11-30	2006-11-27	Сульфамоилсульфонатные пролекарства
CNA2006800449086A CN101316858A (zh)	2005-11-30	2006-11-27	氨磺酰基磺酸酯前药
EP06829354A EP1957513A2 (fr)	2005-11-30	2006-11-27	Promedicaments de sulfonate de sulfamoyle
KR1020087015775A KR20080072956A (ko)	2005-11-30	2006-11-27	술파모일 술포네이트 전구약물
JP2008542678A JP2009517424A (ja)	2005-11-30	2006-11-27	スルファモイルスルホネートプロドラッグ
BRPI0619253-0A BRPI0619253A2 (pt)	2005-11-30	2006-11-27	pró-fármacos de sulfonato de sulfamoìla
US11/605,473 US20070135375A1 (en)	2005-11-30	2006-11-29	Sulfamoyl sulfonate prodrugs
IL191570A IL191570A0 (en)	2005-11-30	2008-05-20	Sulfamoyl sulfonate prodrugs
CR10003A CR10003A (es)	2005-11-30	2008-05-21	Prodrogas de sulfonato de sulfamoilo
EC2008008489A ECSP088489A (es)	2005-11-30	2008-05-30	Prodrogas de sulfonato de sulfamoilo
NO20082915A NO20082915L (no)	2005-11-30	2008-06-27	Sulfamoylsulfonat-prodrug
ZA200805659A ZA200805659B (en)	2005-11-30	2008-06-27	Sulfamoyl sulfonate prodrugs

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE102005057408A DE102005057408A1 (de)	2005-11-30	2005-11-30	Sulfamoylsulfonat-Prodrugs

Publications (1)

Publication Number	Publication Date
DE102005057408A1 true DE102005057408A1 (de)	2007-05-31

Family

ID=37983623

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE102005057408A Ceased DE102005057408A1 (de)	2005-11-30	2005-11-30	Sulfamoylsulfonat-Prodrugs

Country Status (15)

Country	Link
EP (1)	EP1957513A2 (fr)
JP (1)	JP2009517424A (fr)
KR (1)	KR20080072956A (fr)
CN (1)	CN101316858A (fr)
AU (1)	AU2006319380A1 (fr)
BR (1)	BRPI0619253A2 (fr)
CA (1)	CA2632272A1 (fr)
CR (1)	CR10003A (fr)
DE (1)	DE102005057408A1 (fr)
EA (1)	EA200801306A1 (fr)
EC (1)	ECSP088489A (fr)
IL (1)	IL191570A0 (fr)
NO (1)	NO20082915L (fr)
WO (1)	WO2007062874A2 (fr)
ZA (1)	ZA200805659B (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2411003A4 (fr) *	2009-03-24	2012-10-17	Univ Singapore	Utilisation de dérivés de l'artémisinine dans le traitement de l'asthme et de la broncho-pneumopathie obstructive chronique (bpco)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN101987101A (zh) *	2009-08-05	2011-03-23	天津金耀集团有限公司	糖皮质激素芳香基氨磺酰基磺酸酯为活性成分的眼用抗炎组合物
CN101987104A (zh) *	2009-08-05	2011-03-23	天津金耀集团有限公司	一种杂芳香基氨磺酰基羧酸酯碳酸酐酶抑制剂的眼用组合物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2001091797A2 (fr) *	2000-05-31	2001-12-06	Schering Ag	Composes ayant un groupe sulfonamide et compositions pharmaceutiques contenant ces composes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE102004025986A1 (de) *	2004-05-21	2005-12-15	Schering Ag	Steroid-Prodrugs mit androgener Wirkung
DE102004025966A1 (de) *	2004-05-21	2005-12-15	Schering Ag	Estradiol-Prodrugs
DE102004025985A1 (de) *	2004-05-21	2005-12-15	Schering Ag	Estriol- und Estetrol-Prodrugs

2005
- 2005-11-30 DE DE102005057408A patent/DE102005057408A1/de not_active Ceased
2006
- 2006-11-27 AU AU2006319380A patent/AU2006319380A1/en not_active Abandoned
- 2006-11-27 KR KR1020087015775A patent/KR20080072956A/ko not_active Withdrawn
- 2006-11-27 WO PCT/EP2006/011726 patent/WO2007062874A2/fr not_active Ceased
- 2006-11-27 CN CNA2006800449086A patent/CN101316858A/zh active Pending
- 2006-11-27 EA EA200801306A patent/EA200801306A1/xx unknown
- 2006-11-27 EP EP06829354A patent/EP1957513A2/fr not_active Withdrawn
- 2006-11-27 JP JP2008542678A patent/JP2009517424A/ja active Pending
- 2006-11-27 BR BRPI0619253-0A patent/BRPI0619253A2/pt not_active Application Discontinuation
- 2006-11-27 CA CA002632272A patent/CA2632272A1/fr not_active Abandoned
2008
- 2008-05-20 IL IL191570A patent/IL191570A0/en unknown
- 2008-05-21 CR CR10003A patent/CR10003A/es not_active Application Discontinuation
- 2008-05-30 EC EC2008008489A patent/ECSP088489A/es unknown
- 2008-06-27 NO NO20082915A patent/NO20082915L/no not_active Application Discontinuation
- 2008-06-27 ZA ZA200805659A patent/ZA200805659B/xx unknown

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2001091797A2 (fr) *	2000-05-31	2001-12-06	Schering Ag	Composes ayant un groupe sulfonamide et compositions pharmaceutiques contenant ces composes

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2411003A4 (fr) *	2009-03-24	2012-10-17	Univ Singapore	Utilisation de dérivés de l'artémisinine dans le traitement de l'asthme et de la broncho-pneumopathie obstructive chronique (bpco)

Also Published As

Publication number	Publication date
CN101316858A (zh)	2008-12-03
CA2632272A1 (fr)	2007-06-07
CR10003A (es)	2008-08-21
KR20080072956A (ko)	2008-08-07
WO2007062874B1 (fr)	2007-09-27
ECSP088489A (es)	2008-06-30
ZA200805659B (en)	2009-10-28
WO2007062874A3 (fr)	2007-07-12
JP2009517424A (ja)	2009-04-30
NO20082915L (no)	2008-06-27
BRPI0619253A2 (pt)	2011-09-27
WO2007062874A2 (fr)	2007-06-07
IL191570A0 (en)	2008-12-29
AU2006319380A1 (en)	2007-06-07
EA200801306A1 (ru)	2008-10-30
EP1957513A2 (fr)	2008-08-20

Publication	Publication Date	Title
EP1090029B1 (fr)	2002-03-20	14,15-cyclopropanosteroides de la serie des 19-norandrostanes, leur procede de production et preparations pharmaceutiques contenant ces composes
EP2456781B1 (fr)	2017-06-21	Dérivés 17-hydroxy-17-pentafluoroéthyl-estra-4,9(10)-diène-11-acyloxyalcénylphényle, procédés de préparation et utilisation pour le traitement de maladies
EP2623510B1 (fr)	2017-08-23	Dérivés 17-hydroxy-17-pentafluoréthyl-estra-4,9(10)-diène-11-arylés, leur procédé de production et leur utilisation pour le traitement de maladies
DE69429364T2 (de)	2002-08-08	Verwendung von steroidderivaten als arzneimittel
EP0970104B1 (fr)	2006-11-22	Sulfamate de steroide, procede de production et utilisation de cette substance
SG174506A1 (en)	2011-10-28	Novel amide derivatives of steroidal[3,2-c]pyrazole compounds with glucocorticoid activity
EP3083603B1 (fr)	2017-09-13	Dérivés de benzimidazole en tant que ligands de ep4
EP0135762A2 (fr)	1985-04-03	Stéroides
DE60030410T2 (de)	2007-08-30	Steroidsulfatase-Inhibitoren, Verfahren zu ihrer Herstellung und ihre Verwendung
EP1599493B1 (fr)	2010-11-24	Sulfamate estra-1,3,5(10)-triene-3-yle 2-substitue a effet antitumeur
DE102005057408A1 (de)	2007-05-31	Sulfamoylsulfonat-Prodrugs
DE10108271A1 (de)	2002-08-22	Chinolin-, Isochinolin- und Phthalazinderivate als Antagonisten des Gonadotropin freisetzenden Hormons
DE102004025986A1 (de)	2005-12-15	Steroid-Prodrugs mit androgener Wirkung
Templeton et al.	1991	Pregnanes that bind to the digitalis receptor: synthesis of 14-hydroxy-5. beta., 14. beta.-pregnane glycosides from digitoxin and digitoxigenin
US20070135375A1 (en)	2007-06-14	Sulfamoyl sulfonate prodrugs
DE102005057421A1 (de)	2007-05-31	Heteroaromatische Sulfonamid-Prodrugs
DE69815329T2 (de)	2004-04-29	Estra-5(10),7-diene mit östrogener aktivität
EP1594886B1 (fr)	2008-08-27	Sulfamates d-homoestra-1,3,5(10)-triene-3-yle 2-substitues a effet antitumeur
DE102005057224A1 (de)	2007-05-31	Prodrugs ERß-selektiver Substanzen, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
DE102005059222A1 (de)	2007-07-26	11ß-Benzaldoximderivate von D-Homoestra-4,9-dien-3-onen
DE1768351A1 (de)	1971-10-07	Neue Derivate von OEstradiol-17ss-glucosiden

Legal Events

Date	Code	Title	Description
2007-05-31	OP8	Request for examination as to paragraph 44 patent law
2008-03-27	8127	New person/name/address of the applicant	Owner name: BAYER SCHERING PHARMA AKIENGESELLSCHAFT, 13353, DE
2010-07-15	8131	Rejection

DE102005057408A1 - Sulfamoylsulfonat-Prodrugs - Google Patents

Info

Links

Classifications

Landscapes

Priority Applications (16)

Applications Claiming Priority (1)

Publications (1)

Family

ID=37983623

Family Applications (1)

Country Status (15)

Cited By (1)

Families Citing this family (2)

Citations (1)

Family Cites Families (3)

Patent Citations (1)

Cited By (1)

Also Published As

Similar Documents

Legal Events